Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 95

Sort by

Sort Order Select

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Ariela Noy, Stefan K. Barta, Deukwoo Kwon, Robert Baiocchi, Juan Carlos Ramos, Paul Rubinstein, Amy Chadburn, Richard F. Ambinder

Blood (2024) 144 (Supplement 1): 870.

https://doi.org/10.1182/blood-2024-211388

Published: 2024

Journal Articles

Could Active TB be a Major Contributor to the Disparity in Presentation and Mortality for cHL in HIV + and HIV - Individuals in South Africa?

Samantha L Vogt, Nomathemba Tshabalala, Neil A Martinson, Wendy Stevens, Philippa Ashmore, Atul Lakha, Moosa Patel, Jennifer Petr, Wendell Alejo, Richard F. Ambinder, Rena R. Xian, Vinitha Philip

Blood (2023) 142 (Supplement 1): 7398.

https://doi.org/10.1182/blood-2023-188522

Published: 2023

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Catherine S Diefenbach, Opeyemi Jegede, Stephen M Ansell, Christian Steidl, Yasodha Natkunam, David W. Scott, Neha Mehta-Shah, Jennifer E Amengual, Christopher J. Forlenza, Peter D. Cole, Nancy L. Bartlett, Kevin A. David, Ranjana H. Advani, Richard F. Ambinder, Sachdev Thomas, Sami Ibrahimi, Brad S. Kahl

Blood (2023) 142 (Supplement 1): 607.

https://doi.org/10.1182/blood-2023-184531

Published: 2023

Journal Articles

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Amy E. DeZern, Marianna Zahurak, Heather J. Symons, Kenneth R. Cooke, Carol Ann Huff, Tania Jain, Lode J. Swinnen, Philip H. Imus, Nina D. Wagner-Johnston, Richard F. Ambinder, Mark Levis, Leo Luznik, Javier Bolaños-Meade, Ephraim J. Fuchs, Richard J. Jones, Robert A. Brodsky

Blood (2023) 141 (25): 3031–3038.

https://doi.org/10.1182/blood.2023020435

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Nicole Thomas, Kostiantyn Dreval, Daniela S. Gerhard, Laura K. Hilton, Jeremy S. Abramson, Richard F. Ambinder, Stefan Barta, Nancy L. Bartlett, Jeffrey Bethony, Kishor Bhatia, Jay Bowen, Anthony C. Bryan, Ethel Cesarman, Corey Casper, Amy Chadburn, Manuela Cruz, Dirk P. Dittmer, Maureen A. Dyer, Pedro Farinha, Julie M. Gastier-Foster, Alina S. Gerrie, Bruno M. Grande, Timothy Greiner, Nicholas B. Griner, Thomas G. Gross, Nancy L. Harris, John D. Irvin, Elaine S. Jaffe, David Henry, Rebecca Huppi, Fabio E. Leal, Michael S. Lee, Jean Paul Martin, Marie-Reine Martin, Sam M. Mbulaiteye, Ronald Mitsuyasu, Vivian Morris, Charles G. Mullighan, Andrew J. Mungall, Karen Mungall, Innocent Mutyaba, Mostafa Nokta, Constance Namirembe, Ariela Noy, Martin D. Ogwang, Abraham Omoding, Jackson Orem, German Ott, Hilary Petrello, Stefania Pittaluga, James D. Phelan, Juan Carlos Ramos, Lee Ratner, Steven J. Reynolds, Paul G. Rubinstein, Gerhard Sissolak, Graham Slack, Shaghayegh Soudi, Steven H. Swerdlow, Alexandra Traverse-Glehen, Wyndham H. Wilson, Jasper Wong, Robert Yarchoan, Jean C. ZenKlusen, Marco A. Marra, Louis M. Staudt, David W. Scott, Ryan D. Morin

Blood (2023) 141 (8): 904–916.

https://doi.org/10.1182/blood.2022016534

Published: 2023

Includes: Supplemental data

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Stefan K. Barta, Ariela Noy, Marcelo C Pasquini, Naya He, Tiffany Hunt, Carlos Litovich, Uroosa Ibrahim, Robert A. Baiocchi, Richard F. Ambinder

Blood (2022) 140 (Supplement 1): 1847–1848.

https://doi.org/10.1182/blood-2022-165370

Published: 2022

Journal Articles

Clinical Outcomes of Single-Agent Chemotherapy in a Diverse Cohort of Patients with Recalcitrant Cutaneous T-Cell Lymphoma

David M. Weiner, Andrew Ly, Sai Talluru, Richard F. Ambinder, Sima Rozati

Blood (2022) 140 (Supplement 1): 12046.

https://doi.org/10.1182/blood-2022-171218

Published: 2022

Journal Articles

Plasma EBV DNA Methylation: Evidence of EBV Lytic Infection in HIV(+) EBV(+) Plasmablastic Lymphoma

Rena R. Xian, Jennifer Stone, Karin Miller, Lisa Haley, Prisca Mbonu, Moosa Patel, Atul Lakha, Vinitha Philip, Philippa Ashmore, Sugeshnee Pather, Wendy Susan Stevens, Christopher D. Gocke, Neil Martinson, Richard F. Ambinder, Samantha Vogt

Blood (2022) 140 (Supplement 1): 11914–11915.

https://doi.org/10.1182/blood-2022-158540

Published: 2022

Journal Articles

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

Sergiu Pasca, Shiyu Wang, Susan Langan, Aparna Pallavajjala, Lisa Haley, Christopher D Gocke, Wendy S Post, Matthew Budoff, Sabina Haberlen, Todd Brown, Joseph Margolick, Richard F. Ambinder, Lukasz P. Gondek

Blood (2021) 138 (Supplement 1): 4298.

https://doi.org/10.1182/blood-2021-152860

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma

Hema Dave, MDMPH, Mimi Mai, Madeline Terpilowski, BS, Keri Toner, MD, Maja Stanojevic, MD, Morgan Galligan, BS, Abeer Shibli, BS, Melanie Grant, PhD, Christopher Lazarski, PhD, Philip Y Maglo, BS, MPH, Nan Zhang, PhD, Jay Tanna, MS, Richard F. Ambinder, MD, Martha Glenn, MD, Patrick Hanley, PhD, Catherine M. Bollard, MD MBChB

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142422

Published: 2020

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy

Blood (2020) 136 (11): 1284–1297.

https://doi.org/10.1182/blood.2019003959

Published: 2020

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Blood (2019) 134 (Supplement_1): 130.

https://doi.org/10.1182/blood-2019-126787

Published: 2019

NARROW

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Daratumumab with Dose-Adjusted EPOCH Is Feasible in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Could Active TB be a Major Contributor to the Disparity in Presentation and Mortality for cHL in HIV + and HIV - Individuals in South Africa?

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412)

Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Clinical Outcomes of Single-Agent Chemotherapy in a Diverse Cohort of Patients with Recalcitrant Cutaneous T-Cell Lymphoma

Plasma EBV DNA Methylation: Evidence of EBV Lytic Infection in HIV(+) EBV(+) Plasmablastic Lymphoma

Clonal Hematopoiesis Is More Common in People Living with HIV and May be Associated with Increased Prevalence of Cardiovascular Disease

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only